SEER is an authoritative source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the U.S. population.
(This code is effective for cases diagnosed 2010 and later. For cases diagnosed prior to 2010, see code 9861/3.)
This AML has a generally poor prognosis. Elevated white bloodcell counts are most predictive of shorter overall survival and increased BM blasts are associated with shorter disease free survival. Very limited data available regarding treatment or survival.
In adults the WBC is generally lower than other AML types. The BM may have morphologic and cytochemical features of any FAB subtype of AML other than acute promyelocytic leukemia and acute megakaryoblastic leukemia.
If the leukemia occurs before or simultaneously with Myeloid Sarcoma (9930/3), see M3 and Module 5:PH10.